A Phase 3 interventional study of Allopurinol and Rasburicase in Adult Acute Lymphocytic Leukemia and High-grade Lymphoma, sponsored by Goethe University. Completed at 1 site in Germany. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-03-17.
Sponsored by Goethe University · Phase 3, Interventional, and Treatment
In this study the efficacy and tolerability of two approaches to treat and prevent hyperuricemia is tested in patients with acute lymphoblastic leukemia or high-grade lymphoma with high risk of tumor lysis syndrome. Both arms are compared by randomisation. In one arm patients receive during pre-phase chemotherapy conventional prophylaxis with allopurinol whereas in the other arm Rasburicase is used.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 80 is above the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Goethe University is the lead sponsor of 97 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Allopurinol · Drug: Rasburicase
renal function, uric acid, electrolytes, adverse events and mortality in pre-phase and the two following cycles of chemotherapy, time and dose compliance of chemotherapy
after cycle 1
Time frame: 3 weeks
response rate, incidence of tumor lysis syndrome
after cycle 1
Time frame: 3 weeks
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Goethe University